Regeneron Pharmaceuticals, Inc. $REGN Stock: AIA Group Ltd Decreases Holdings

Key Points

• AIA Group reduced its Regeneron stake by 37.2% in the third quarter, selling 3,254 shares and retaining 5,482 shares valued at about $4.16 million.
• Regeneron reported quarterly EPS of $20.07, beating the $16.51 consensus, while revenue of $5.12 billion exceeded expectations and rose 36.3% year over year.
• Company insiders sold 20,789 shares worth about $18.8 million over the past 90 days. Analyst sentiment remained broadly positive, with a “Moderate Buy” consensus rating and an average price target of $898.97.

AIA Group Ltd cut its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 37.2% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 5,482 shares of the biopharmaceutical company's stock after selling 3,254 shares during the period. AIA Group Ltd's holdings in Regeneron Pharmaceuticals were worth $4,157,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of the business. Western Wealth Management LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the first quarter worth about $26,000. Armstrong Advisory Group Inc. raised its holdings in shares of Regeneron Pharmaceuticals by 466.7% during the third quarter. Armstrong Advisory Group Inc. now owns 34 shares of the biopharmaceutical company's stock valued at $26,000 after acquiring an additional 28 shares during the last quarter. Mowery & Schoenfeld Wealth Management LLC purchased a new position in shares of Regeneron Pharmaceuticals in the second quarter valued at approximately $29,000. Trust Co. of Vermont purchased a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth approximately $29,000. Finally, Fiduciary Financial Advisors purchased a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth approximately $29,000. Hedge funds and other institutional investors own 83.31% of the company's stock.

Insider Transactions at Regeneron Pharmaceuticals

In other news, insider Andrew Murphy sold 4,147 shares of the company's stock in a transaction that occurred on Wednesday, October 14th. The shares were sold at an average price of $772.70, for a total value of $3,204,386.90. Following the transaction, the insider directly owned 47,833 shares in the company, valued at approximately $36,960,559.10. This represents a 7.98% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Joseph Larosa sold 4,466 shares of the stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $965.49, for a total transaction of $4,311,878.34. Following the transaction, the executive vice president directly owned 38,906 shares of the company's stock, valued at $37,563,353.94. The trade was a 10.30% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 20,789 shares of company stock worth $18,766,698. 6.97% of the stock is owned by company insiders.

Regeneron Pharmaceuticals Stock Down 4.4%

Shares of NASDAQ REGN opened at $930.67 on Thursday. The company has a 50 day simple moving average of $800.69 and a 200-day simple moving average of $741.11. The company has a market capitalization of $95.82 billion, a P/E ratio of 20.55, a P/E/G ratio of 1.45 and a beta of 0.10. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.35 and a quick ratio of 3.66. Regeneron Pharmaceuticals, Inc. has a 1 year low of $591.52 and a 1 year high of $991.73.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings data on Friday, October 30th. The biopharmaceutical company reported $20.07 EPS for the quarter, beating analysts' consensus estimates of $16.51 by $3.56. The firm had revenue of $5.12 billion for the quarter, compared to analysts' expectations of $4.58 billion. Regeneron Pharmaceuticals had a return on equity of 16.01% and a net margin of 28.51%. The firm's quarterly revenue was up 36.3% on a year-over-year basis. During the same period in the prior year, the firm posted $11.83 earnings per share. On average, equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 51.64 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 3rd. Stockholders of record on Friday, November 20th will be paid a $0.94 dividend. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date of this dividend is Friday, November 20th. Regeneron Pharmaceuticals's payout ratio is 8.30%.

Trending Headlines about Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Bank of America added REGN to its Value 10 list, a favorable signal about the stock’s value appeal. BofA adds REGN to Value 10 list
• Positive Sentiment: Recent analyst coverage points to higher price targets and expectations for appreciation. Separately, Zacks said solid earnings-estimate revisions could help the shares continue gaining. These views follow Regeneron’s recent quarterly results, which beat consensus on earnings and revenue. RBC raises Regeneron price target Zacks on earnings estimate revisions
• Negative Sentiment: Recent disclosures show EVP Joseph Larosa sold 4,466 shares and director Christine Poon sold 7,830 shares on November 2; Poon’s sale cut her direct holding by 60%. Director Kathryn Guarini also sold 400 shares under a pre-arranged trading plan. The larger transactions could raise concerns about insider sentiment, though sales alone do not indicate a change in the company’s business outlook. Larosa sale filing Poon sale filing Guarini sale filing

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on REGN. Zacks Research upgraded shares of Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Monday, September 28th. Bank of America upped their price objective on shares of Regeneron Pharmaceuticals from $908.00 to $1,030.00 and gave the company a "buy" rating in a research note on Monday. Wall Street Zen upgraded shares of Regeneron Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Sunday, September 20th. Weiss Ratings upgraded Regeneron Pharmaceuticals from a "hold (c)" rating to a "hold (c+)" rating in a research report on Monday. Finally, Royal Bank Of Canada increased their price target on Regeneron Pharmaceuticals from $810.00 to $913.00 and gave the company a "sector perform" rating in a report on Monday. One analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus price target of $898.97.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.